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Available online 12 November 2017Objectives: To examine the longitudinal mutual association between endothelial dysfunction and arterial stiff-
ness, and also to determine which of the two variables was more closely associated with the progression of sub-
clinical organ damage.
Methods: The brachial-ankle pulse wave velocity (baPWV), carotid intima-media thickness (CIMT), estimated
glomerular ﬁltration rate, microalbuminuria and ﬂow-mediated vasodilatation of the brachial artery (FMD)
were measured three times at 1.5-year intervals in 674 Japanese patients receiving antihypertensive treatment.
Results: The change of the baPWV during the study period was larger in the subjects with baseline FMD values in
the lowest tertile as compared to those with baseline FMD values in the highest tertile. The change of the CIMT
was smaller in the subjects with baseline baPWV values in the lowest tertile than in those with baseline
baPWV values in the highest tertile. After the adjustment, the FMD value at the baseline was inversely associated
with the baPWV at the end of the study period (beta = −0.07, p = 0.01), although, the reverse association
was not signiﬁcant. The baPWV, but not the FMD value, at the baseline was associated with the CIMT (beta =
0.06, p= 0.04) measured at the end of the study period.Keywords:
Hypertension
Endothelial function
Arterial stiffness
Atherosclerosis
Renal functionthe brachial artery; baPWV, brachial-ankle pulse wave velocity; CIMTmean, the mean intima-media thickness of the common
ickness of the common carotid artery; eGFR, the estimated glomerular ﬁltration rate; UACR, urinary albumin-to-creatinine
ertile 3 [T3] = highest).
eliability and freedom from bias of the data presented and their discussed interpretation".
Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, 160-0023 Tokyo, Japan.
ama).
land Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
162 H. Tomiyama et al. / International Journal of Cardiology 253 (2018) 161–166Conclusions: In hypertension, endothelial dysfunctionwas associatedwith the progression of arterial stiffness, al-
though the reverse association was not conﬁrmed. The increased arterial stiffness rather than endothelial dys-
function may be more closely associated with the progression of atherosclerotic vascular damage, and the
endothelial dysfunction-arterial stiffness-atherosclerosis continuummay be important in hypertension.
© 2018 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
For the prevention of cardiovascular disease in patients with hyper-
tension, prevention of the progression of subclinical organ damage is
crucial [1,2]. Vascular dysfunction is thought to contribute to the pro-
gression of subclinical organ damage [3]. In clinical settings, FMD, a
marker of endothelial function, and PWV, a marker of arterial stiffness,
which is affected by abnormalities of the intima and media, have been
used for the assessment of vascular function, and both are known to
be independent predictors of future cardiovascular events [4,5,6]. Endo-
thelial dysfunction is thought to be associated with the progression of
arterial stiffness, atherosclerosis and renal damage [4,7,8,9,10,11]. On
the other hand, arterial stiffness is also thought to augment endothelial
dysfunction [12] and to be associated with the progression of athero-
sclerosis and renal damage, even via mechanisms other than endotheli-
al dysfunction [4,7,13,14,15,16]. However, the signiﬁcances of these
associations have not yet been fully clariﬁed. The present multicenter
prospective observational study was conducted to examine whether
progression of endothelial dysfunction and progression of arterial stiff-
ness are mutually associated, and also to determine which of the two
variables is more closely associated with the progression of atheroscle-
rotic vascular damage as assessed by carotid ultrasound examination
and/or renal damage.
2. Methods
The study design has been reported elsewhere [17]. The study was conducted in con-
formity with the principles of the Declaration of Helsinki, and with the approval of the
Ethics Committee of Tokyo Medical University (the core center of the FMD-J study) (No.
2456) as well as of the Ethics Committee of each of the other participating institutions.
Written informed consent was obtained from each of the study participants prior to
their participation in the FMD-J study. The details of the study subjects, study protocol
and measurement are described in the supplementary ﬁle.
2.1. Study subjects
The subjects enrolled were hypertensive patients receiving antihypertensive treat-
ment, with a blood pressure of b150/95 mm Hg, who had been under follow-up at any
of the participating centers for at least 6 months [17]. As shown in Supplementary Fig. 1,
all the analyses were successfully completed in 674 patients.
2.2. Study protocol
This multicenter prospective observational study was conducted with the participa-
tion of 17 university hospitals in Japan, from June 2010 to October 2015. Measurements
of the FMD, brachial-ankle PWV (baPWV), markers of subclinical organ damage and
blood parameters to assess the conventional risk factors for CVD were conducted a total
of three times until the end of the 3-year study period {i.e., at the start of the study (base-
line), at 1.5 years after the start of the study, and at 3 years after the start of the study (end
of the study period)} [17].
2.3. Measurements
2.3.1. Flow-mediated vasodilatation of the brachial artery
FMD was measured from A-mode images of the brachial artery as a signal of the
intima-media complex (EF, Unex Co. Ltd., Nagoya, Japan) [17,18]. The FMD assessment
at each of the participant institutions was conducted in a blindedmanner. In our previous
study, we determined the correlation coefﬁcient between the FMD values measured at
each institution and the FMD value measured at a core laboratory (n = 880), and
found a good correlation coefﬁcient (R = 0.838; P b 0.001) [18].
2.3.2. Ultrasonographic examination of the carotid arteries
The records of the carotid artery obtained at each institution were uploaded as JPEG
ﬁles to thewebsite of the FMDJ-study [17,19], and themeasurements were then conductedat a core laboratory (University of Tsukuba). A single expert analyst who was blinded to
clinical information about the participants measured the mean intima-media thickness of
the common carotid artery (CIMTmean) and the maximum intima-media thickness of
the common carotid artery (CIMTmax) in all the subjects, using an automatic IMTmeasure-
ment software (Vascular Research Tools 5, Medical Imaging Applications) [20].
2.3.3. Pulse wave velocity
The baPWV was measured using a volume-plethysmographic apparatus (Form/ABI,
Omron Health Care Co. Ltd., Kyoto, Japan), in accordance with a previously described
method [21]. The instrument that was used tomeasure the baPWVwas also used tomea-
sure the ankle-brachial pressure index (ABI). Patients with ABI values of b0.90 and/or atri-
al ﬁbrillation were excluded from the analyses, because the measured baPWV values in
such patients are known to be unreliable. No facility for baPWV measurement was avail-
able at 2 institutions.
2.3.4. Laboratory measurements
Fasting blood samples (5 ml) for laboratory measurements were collected from the
subjects on the day of the FMD measurement. The estimated glomerular ﬁltration rate
(eGFR) and urinary albumin-to-creatinine ratio (UACR) were calculated.
2.4. Statistical methods
Wehave described ourmethod for estimating the sample size for the present study in
a previously published report [17,22]. It was determined that a total of 598 subjects would
be needed to obtain at least 80% statistical power at a 2-sided signiﬁcance level of 0.05 to
detect a signiﬁcant difference of the CIMTmean between the 2 groups, and a total of 642
subjects would be needed to detect a signiﬁcant difference of the UACR between the 2
groups [17,23].
Differences in the measured values between each variable were assessed using the
paired t-test for continuous variables and McNemar's non-parametric test for categorical
variables. The subjects were divided into tertiles of the baPWV and FMD values recorded
at the study baseline. Then, the differences in the changes between subject groups with
values in the lowest and highest tertiles were compared using a general linear model
(GLM) analysis model with and without adjustments. The relationships among the vari-
ables were assessed by measuring the Pearson's correlation coefﬁcients and by multivar-
iate linear regression analysis with adjustments.
For the adjustments, the covariates inModel 1were the age, gender, bodymass index,
systolic blood pressure, smoking status (current smoker = 1; non-current smoker = 0),
daily alcohol intake (ethanol g/day), daily exercise level (Mets/day), LDLC, HDLC, TG and
Crnn, presence/absence of diabetes mellitus, history of medication use (statins, renin-
angiotensin system blockers, and calcium channel blockers [not receiving medication =
0; receiving medication = 1 for each medication]).
All the other analyses were conducted using the SPSS software (version 24.0; IBM/
SPSS Inc., Armonk, NY, USA). P b 0.05 was considered to indicate a statistically signiﬁcant
difference in all the statistical tests.
3. Results
The numerical data that were available for completion of all the
analyses in this study are summarized in Supplementary Fig. 1. The clin-
ical characteristics of the subjects in whom all the analyses could be
completed are summarized in Table 1. The CIMTmean, CIMTmax
and UACR showed signiﬁcant increase, while the diastolic blood pres-
sure and eGFR showed signiﬁcant decrease during the study period
(Table 1).
Fig. 1 and Fig. 2 show the changes in the markers of vascular func-
tion, vascular damage and renal damage during the study period
{i.e., from the baseline to 1.5 years after the start of the study (ﬁlled
circles) and from the baseline to the end of the study period (clear
circles)} in the study subjects divided into three groups according to
the tertile ranges (tertile 1 [T1] = lowest and tertile 3 [T3] = highest)
of the baPWV and FMD values measured at the study baseline (the
T1-baPWV to T3-baPWV groups and the T1-FMD to T3-FMD groups,
respectively).
Table 1
Clinical characteristics of the study subjects at the baseline and their changes during the
study period.
Parameter Baseline 1.5 years 3 years
Number 674
Age 62 ± 9
Gender (m/f) 382/292
BMI 24.7 ± 3.6 24.7 ± 3.7 24.6 ± 3.8
SBP (mm Hg) 134 ± 14 133 ± 14 133 ± 15
DBP (mm Hg) 80 ± 10 79 ± 10* 78 ± 10*
BP controlled (%) 448 (67) 441 (65) 444 (66)
Smoking# (%) 75/663 (11) 68/664 (10) 67/672 (10)*
Alcohol# (%)
Ethanol g
309/663 (44)
15 ± 22
288/632 (45)
14 ± 21
283/641 (44)
14 ± 22
Exercise habit# (%)
Mets/day
365/647 (56)
608 ± 1213
368/617 (60)*
634 ± 927
382/631 (61)*
654 ± 930
LDLC (mmol/L) 3.01 ± 0.76 2.92 ± 0.74* 2.89 ± 0.75*
HDLC (mmol/L) 1.51 ± 0.40 1.53 ± 0.40* 1.53 ± 0.40*
TG (mmol/L) 1.47 ± 0.86 1.44 ± 0.82 1.37 ± 0.73*
FPG (mmol/L) 5.83 ± 1.04 5.80 ± 1.12 5.81 ± 1.18
Diabetes (%) 115 (17) 104 (15) 123 (18)
Crnn (μmol/L) 68 ± 18 69 ± 19* 71 ± 25*
CRP (mg/L) 0.76 ± 0.20 0.78 ± 0.22* 0.80 ± 0.29*
FMD (%) 4.89 ± 2.77 5.02 ± 2.97 5.00 ± 3.08
BRdia (mm) 4.13 ± 0.65 4.15 ± 0.62 4.10 ± 0.65
CIMTmean (mm) 0.77 ± 0.15 0.77 ± 0.15 0.78 ± 0.16*
CIMTmax (mm) 1.06 ± 0.26 1.06 ± 0.27 1.07 ± 0.27*
baPWV (cm/s) 1621 ± 295 1603 ± 357 1625 ± 293
eGFR (ml/min/1.73 m2) 74 ± 17 72 ± 17 70 ± 17*
UACR (mg/g creatinine) 26 ± 118 33 ± 218 38 ± 274*
FRSscore 10 ± 7 (n= 653) 10 ± 7 (n= 659) 10 ± 7 (n= 661)
Medications
CCBs (%) 431 (64) 424 (63) 441 (65)
RAbs (%) 439 (65) 421 (63) 436 (65)
BBs 116 (17) 127 (19) 134 (20)*
Diuretics 177 (26) 149 (22)* 136 (20)*
Others 46 (7) 60 (9) 53 (8)
Medication for DM 70 (10) 67 (10) 80 (12)
Statins 203 (30) 214 (32)* 238 (35)*
Abbreviations: Data are expressed asmeans± standarddeviation; Baseline=at the study
baseline; 1.5 years= 1.5 years after the start of the study; 3 years= 3 years after the start
of the study; BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic
blood pressure; BP controlled = number of subjects in whom the BP was controlled to ≤
140/90 mm Hg; Smoking# = number of current smokers; Alcohol# = number of current
drinkers; ethanol = daily ethanol intake; Exercise habit# = number of subjects engaging
in habitual exercise; Mets/day = daily exercise level expressed in Mets; # = data for
smoking, alcohol intake, and habitual exercise were not available for some cases (the de-
nominators show the number of subjects for whom the data were available); TC= serum
levels of total cholesterol; LDLC = serum level of low-density lipoprotein cholesterol
calculated by the Friedewald formula; HDLC = serum level of high-density lipoprotein
cholesterol; TG = serum level of triglycerides; FPG = fasting plasma glucose level;
Diabetes = number of subjects diagnosed as having diabetes mellitus; Crnn = serum
level of creatinine; CRP = serum level of C-reactive protein; FMD = ﬂow-mediated
dilatation of the brachial artery; BRdia = baseline diameter of the brachial artery;
CIMTmean = mean intima-media thickness of the common carotid artery; CIMTmax,
maximum intima-media thickness of the common carotid artery; Cdia = diameter
of the common carotid artery; baPWV = brachial-ankle pulse wave velocity; eGFR =
estimated glomerular ﬁltration rate; UACR = urinary albumin/creatinine ratio; FRS =
Framingham risk score; n = number of patients in whom the FRS had been calculated;
CCB = number of subjects taking calcium channel blockers; RAb = number of subjects
taking renin-angiotensin system blockers; BB= number of subjects taking beta-blockers;
Diuretics = number of subjects taking diuretics; Others = number of subjects taking an-
tihypertensive medication(s) other than a CCB, RAb, BB or diuretic; Medication for DM=
number of subjects taking medication(s) for diabetes mellitus; Statin = number of sub-
jects taking statins; *, p b 0.05 vs. baseline.
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end of the study period was lower in the T3-FMD group than in the T1-
FMD group. This difference remained signiﬁcant even after adjustments
for the covariates in Model 1 plus the baPWV at the baseline. While the
crude value of the change of the FMD from the baseline to the end of the
study period was higher in the T3-baPWV group and then in the T1-
baPWV group, this difference was no longer signiﬁcant after adjust-
ments for the covariates in Model 1 plus the FMD at the baseline.The change of the CIMTmean from the baseline to the end of the
study period was higher in the T2- and T3-baPWV groups than in the
T1-baPWV group, even after adjustments for model 1 covariates plus
the CIMTmean at the study baseline (Fig. 1). The crude value of the
change of the CIMTmean from the baseline to 1.5 years after the start
of the study was higher in the T3-FMD group than in the T1-FMD
group. However, this difference was no longer signiﬁcant after adjust-
ment for the covariates in Model 1 plus the CIMTmean at the baseline
(Fig. 1). On the other hand, the crude value of the change of the
CIMTmax from the baseline to the end of the study period was similar
among the three tertile range groups (Fig. 1). In the assessment of the
relationships among the changes in the vascular biomarkers from the
baseline to the end of study period, the change of the baPWV showed
a signiﬁcant correlation with the change of the FMD (R=−0.09, p=
0.036), but not with that of the CIMTmean (R=−0.06, p= 0.148).
As shown in Fig. 2, the crude value of the change of the eGFR
from the baseline to 1.5 years after the start of the study was higher in
the T3-baPWV group than in the T1-baPWV group, and the crude
value of the change of the eGFR from the baseline to the end of the
study was lower in the T3-FMD group than in the T1-FMD group. How-
ever, these differences were no longer signiﬁcant after adjustments for
the covariates of model 1 plus the baseline eGFR value. The change of
the UACR from the baseline to the end of the study period was similar
among the T1 to T3-FMD groups as well as among the T1- to T3-
baPWV groups.
The clinical characteristics at the baseline of the subjects divided into
three groups according to the tertile ranges of the baPWV and FMD
values measured at the study baseline are described in Supplementary
Table 1.
Table 2 summarizes the relationship of the FMD and baPWV values
measured at the baseline with their opponent variable, CIMT, eGFR
and UACR measured at the end of the study period. Even after adjust-
ments for covariates of model 1 plus the baseline value of the outcome
variable, the FMD value measured at the baseline showed a signiﬁcant
inverse association with the baPWV measured at the end of the study
period. On the other hand, the reverse association could not be con-
ﬁrmed, namely, the baPWVmeasured at the baseline showed no signif-
icant inverse associationwith the FMD valuemeasured at the end of the
study period. Furthermore, the baPWV, but not the FMD, value mea-
sured at the baseline showed a signiﬁcant association with the
CIMTmean, but not the CIMTmax, measured at the end of the study pe-
riod. Neither the FMD value nor the baPWV measured at the baseline
showed any signiﬁcant relationship with the eGFR or UACR measured
at the end of the study period (Table 2).
4. Discussion
The novel ﬁndings of the present studywere that a lower FMD value
at the baselinewas associated with a higher longitudinal increase of the
baPWV. In addition, a higher value of the baPWV, but not lower value of
the FMD, at the baseline was associated with a higher longitudinal in-
crease of the CMIT; no such association was observed with the changes
of the UCAR/eGFR. Thus, one-way relationships of the FMD with the
baPWV(lower the FMDvalue at the baseline, higher the longitudinal in-
crease of the baPWV) and of the baPWV with the CIMT (higher the
baPWV at the baseline, higher the longitudinal increase of the CIMT)
were observed in the present study.
4.1. Flow-mediated vasodilatation and arterial stiffness
Several experimental studies have reported that imbalances of vaso-
active substances derived from the endothelium, such as nitric oxide or
endothelin, can cause functional increase of the arterial stiffness via
changing the arterial tone, and also structural increase of the arterial
stiffness via inducing abnormal medial vascular smooth muscle cell be-
haviors and altering the medial extracellular matrix composition and
Fig. 1. Changes in the markers of vascular function and vascular damage during the study period in the subjects divided into three groups according to the tertile range of the baPWV or
FMD values at the study baseline. Abbreviations: FMD= ﬂow-mediated vasodilatation of the brachial artery; baPWV= brachial-ankle pulse wave velocity; CIMTmean=mean intima-
media thickness of the common carotid artery; CIMTmax=maximum intima-media thickness of the common carotid artery; T1= lowest tertile; T2= intermediate tertile; T3=highest
tertile; del = delta change of variable;−base = at the baseline; 1.5 year= delta change from the baseline to themeasurement at 1.5 years; end= delta change from the baseline to the
end of the study period; * = p b 0.05 vs. T1 without adjustments; †= p b 0.05 vs. T1 after adjustments; adjustment = adjusted for covariates of Model 1 plus the value of the outcome
variable at the baseline;
Fig. 2. Changes in the markers of renal damage during the study period in the subjects divided into three groups according to the tertile range of the baPWV or FMD values at the study
baseline. Abbreviations: eGFR = estimated glomerular ﬁltration rate; UACR = urinary albumin/creatinine ratio; for the eGFR, crnn was excluded as a covariate for adjustment; other
abbreviations are as described in the ﬁgure legend for Fig. 1.
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Table 2
Relationships of the ﬂow-mediated vasodilation and brachial-ankle pulse wave velocity
values at the ﬁrst examination with the values of their opponent variables and markers
of subclinical organ damage at the third examination.
Pearson's correlation Multivariate analysis
Outcome R P-value B Beta P-value
Explained variable = FMD at the baseline of study period
baPWV-e −0.13 b0.01 −7.43 −0.07 0.01
IMTmean-e −0.07 0.09 0.01 0.01 0.55
IMTmax-e −0.05 0.26 – – –
eGFR-e −0.07 0.09 −0.14 −0.02 0.27
UACR-e −0.02 0.63 – – –
Explained variable = baPWV at the baseline of study period
FMD-e −0.03 0.43 – – –
IMTmean-e 0.28 b0.01 0.01 0.06 0.04
IMTmax-e 0.25 b0.01 0.01 0.04 0.21
eGFR-e 0.02 0.54 – – –
UACR-e −0.13 b0.01 0.02 0.04 0.35
Abbreviations: outcome = outcome variable;−e = at the end of the study period; R =
Pearson's correlation coefﬁcient; B = non-standardized coefﬁcient in multivariate analy-
sis; beta = standardized coefﬁcient in multivariate analysis; adjustment = adjusted
Model 1 plus the value of the outcome variable at the baseline added as a covariate (for
eGFR, crnn was excluded as a covariate); other abbreviations are as described in the foot-
note for Table 1.
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studies have reported the existence of a signiﬁcant association between
endothelial dysfunction and increased arterial stiffness [24], the present
study is the ﬁrst prospective clinical study to demonstrate a signiﬁcant
association of endothelial dysfunction (assessed by FMD) with the lon-
gitudinal progression of the arterial stiffness (assessed by the baPWV).
As this associationwas signiﬁcant even after adjustment for blood pres-
sure, it is reasonable to assume that endothelial dysfunction may con-
tribute to the progression of structural arterial stiffness. In addition,
the baPWV also decreased signiﬁcantly from the baseline to the end of
the study period in the subject group with baseline FMD values in the
highest tertile. While arterial stiffness has been demonstrated as an in-
dependent risk factor for future cardiovascular events [19], no strategy
for de-stiffening of the arteries has been established yet. The results of
the present study serve to emphasize that maintenance of a healthy en-
dothelium and/or improvement of endothelial dysfunction are impor-
tant to counteract the progression of arterial stiffness.
On the other hand, increased arterial stiffness causes greater expo-
sure of the endothelium to hemodynamic load [12], which has been
speculated to augment endothelial dysfunction via reducing NO bio-
availability and increasing oxidative stress [25]. However, in the present
study, the baPWVmeasured at the baseline was not found to be associ-
ated with the FMD measured at the end of the study period. Further-
more, there were no signiﬁcant differences in the delta-change of FMD
during the study period among subjects with baseline baPWV values
in the lowest, intermediate and highest tertiles (T1, T2 and T3). Thus,
we could not conﬁrm augmentation of endothelial dysfunction by in-
creased arterial stiffness in the present study.
4.2. Vascular function and subclinical organ damage
Several experimental studies havedemonstrated that not only endo-
thelial dysfunction, but also abnormal medial vascular smooth muscle
cell behaviors and/or alterations of themedial extracellularmatrix com-
position and organization contribute to atherosclerosis [26,27]; these
pathophysiological abnormalities of the intima and media also contrib-
ute to arterial stiffness [7]. Among the risk factors for cardiovascular dis-
ease, hypertension is known as a major determinant of arterial stiffness
[28]; therefore, the combination of endothelial dysfunction with patho-
physiological abnormalities of themediamay contribute to the progres-
sion of atherosclerosis in hypertension. Therefore, as compared toendothelial dysfunction (assessed by FMD), arterial stiffness (assessed
by the baPWV) may show a closer association with the progression of
atherosclerotic vascular damage (assessed by CIMT) in subjects with
hypertension under antihypertensive medication. In addition, the
CIMTmean is actually ameasure of arterial wall hypertrophy, which de-
termines the arterial stiffness to some extent. That may serve as a plau-
sible explanation for why the baPWV was associated with the changes
of the CIMTmean, but not with those of the CIMTmax.
In two previous prospective studies, the FMD value measured at the
study baselinewas found to be an independent predictor of the progres-
sion of carotid atherosclerosis during the study period [8,9]. However,
FMD is also known to show intra-subject variability [29], and the longi-
tudinal intra-subject variations of the control status of the cardiovascu-
lar risk factors also affect the FMD value [4]. However, in the present
longitudinal study, no longitudinal association could be conﬁrmed be-
tween the FMD and CIMT. A plausible explanation for these conﬂicting
ﬁndings is as follows; the MESA study has reported that the use of anti-
hypertensive medication(s) was associated with slower progression of
the CIMT [30]; the discrepant ﬁndings between our studies and the
two aforementioned studies could be attributable to the fact that
b50% of the study participants in the two previous studies were under
antihypertensive medication [8,9].
Several cross-sectional studies have reported the existence of an as-
sociation between FMD and eGFR decline/microalbuminuria in patients
with diabetes mellitus and/or hypertension [10,11]. The PWV has been
reported to be a signiﬁcant predictor of eGFR decline and/or
microalbuminuria [15,16]. However, in the present study, we could not
conﬁrm any signiﬁcant longitudinal relationship of either FMD or
baPWVwith eGFRdecline/microalbuminuria. The plausible explanations
for these ﬁndings are as follows; 1) Antihypertensive medications, espe-
cially renin-angiotensin system blockers (RAS blockers), exert beneﬁcial
effects on the FMD, PWV, eGFR and microalbuminuria [3,4,31];
2)Microalbuminuria and reduced glomerularﬁltration rate are observed
even in subjects with preclinical hypertension (i.e., prehypertension/
high normal blood pressure) [32,33]. These aspects of renal damage are
mainly a consequence of arteriolar lesions, and usually precede stiffness
or other functional abnormalities of the large arteries. Further longitudi-
nal studies are needed to clarify the associations among endothelial func-
tion, arterial stiffness and renal function decline in patients with early-
stage hypertension and also in those under antihypertensivemedication,
especially RAS blockers.4.3. Study strengths and limitations
The strengths of the present study were as follows: all steps were
taken in the study to reduce any measurement bias (i.e., acceptable re-
liability of the FMD assessment at individual participating institutions
was ensured [18], and the CIMTs were analyzed at a core laboratory
[19]). The study limitations were as follows: 1) a clear FMD image
could not be obtained in 10% of the study subjects, and the 3-year
follow-up could not be completed in 20% of the study subjects. Howev-
er, the clinical characteristics of the subjects included in and excluded
from the analyses were mostly similar (Supplementary Table 2);
2) the change in the shear rate before and after hyperemia is thought
to affect the measured value of FMD, and normalization of the FMD
value by the change in the shear rate has been proposed [34]; however,
in this study, we did not measure this normalized FMD value;
3) nitroglycerine-induced vasodilatation was not employed in the pres-
ent study; 4) further study is proposed to conﬁrm the signiﬁcance of the
endothelial dysfunction-arterial stiffness-atherosclerosis continuum in
subjects with risk factors for cardiovascular diseases other than hyper-
tension; 5) we did not examine the effects of antioxidant vitamin intake
on the FMDand PWVvalues [35]; 6)we did not examine the association
of vascular dysfunction with hypertensive cardiac abnormalities
(i.e., left ventricular hypertrophy and/or cardiac diastolic dysfunction).
166 H. Tomiyama et al. / International Journal of Cardiology 253 (2018) 161–1665. Conclusions
Endothelial dysfunction (assessed by FMD) was associated with the
longitudinal progression of arterial stiffness, although the reverse asso-
ciation was not conﬁrmed. In subjects with lower FMD values at the
baseline, the arterial stiffness increased during the study period. In-
creased arterial stiffness, which is affected to a greater extent by intimal
and medial abnormalities than by endothelial dysfunction, was more
closely associated with the progression of atherosclerosis, although no
such associationwas foundwith the progression of renal damage. Final-
ly, the endothelial dysfunction-arterial stiffness-atherosclerosis contin-
uum may be important in hypertension.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2017.11.022.
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